BioSpace News Archive

SparingVision (“the Company”), a genomic medicine company developing vision-saving treatments for ocular diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug application (IND) for SPVN06, its lead gene independent therapy for the treatment of retinitis pigmentosa (RP), a form of rod-cone dystrophy (RCD) and the most prevalent inherited retinal disease (IRD).

Renalytix plc announced additional highlights from the publication of data from a clinical utility study demonstrating that use of KidneyIntelX risk assessment in the primary care setting resulted in improved clinical decision making and observed clinical outcomes for 1,686 patients in the earliest stages of diabetic kidney disease.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, shared webcast information for the virtual investor event that the Company will host on December 14, 2022, from 8:00-9:30 AM ET.

Athira Pharma, Inc. announced it will host a virtual research and development event titled “Enhancing the HGF/MET System to Fight Neurodegenerative Diseases,” on December 7, 2022, from 2:00 p.m. to 3:30 p.m. EST.

Krystal Biotech, Inc. a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced that the Company will participate in the BofA Securities 2022 Biotech SMID Cap Conference, which is taking place virtually from December 7-8.

Humacyte, Inc. today announced presentations on the Company’s Human Acellular Vessel (HAV) by Ukrainian surgeon collaborators.

Asuragen, a Bio-Techne brand and Oxford Nanopore Technologies plc, announce a collaboration to develop assays designed to deliver more accurate and reliable options for reproductive health and carrier screening.

Aucta Pharmaceuticals, Inc. (“Aucta Pharmaceuticals”), announced today the U.S. approval of a generic version of Perforomist® [1] (formoterol fumarate) Inhalation Solution.

Senhwa Biosciences, Inc. announced that their first in class new drug Pidnarulex (CX-5461) has been successfully selected to the anticancer pipeline of NIH-sponsored NExT Program (NCI Experimental Therapeutics Program), which will foster the exploration of its therapeutic potential in unmet medical needs and advancement to market.

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today publication of abstracts by ESMO-IO showing that at the time of abstract data cutoff, Compugen’s COM701 (anti-PVRIG) in dual and triple combination with nivolumab ± BMS-986207 demonstrated preliminary anti-tumor activity and immune activation in platinum resistant ovarian cancer patients and was well tolerated.